As the popularity of prescription weight-loss drugs like Ozempic and Mounjaro continues to rise, so do reports of severe side effects, including a troubling new concern: blindness. Recent evidence is raising alarms about the potential dangers of these drugs, particularly due to the active ingredients semaglutide and tirzepatide, which have been linked to inflammation and blood flow blockages in the eyes.
A new study conducted by researchers at the University of Utah and published in JAMA Ophthalmology highlights nine cases of vision complications in patients taking these weight-loss and diabetes medications. The reported conditions include eye strokes, partial blindness, optic neuritis, and eye bleeding. This is just the latest study to suggest a connection between Ozempic and significant vision issues, following previous research from Odense University Hospital in Denmark, which linked Ozempic and Wegovy (another weight-loss drug) to eye strokes.
Despite the mounting evidence of serious health risks, Denmark-based Novo Nordisk, the maker of Ozempic and Wegovy, continues to rake in massive profits. A Bloomberg analysis from last year projected sales of the drugs could hit $65 billion—over five times the amount the company claims to have spent on their development. The widespread use of Ozempic-like drugs, even in Hollywood, where they’ve been reportedly microdosed as a trend, demonstrates Big Pharma’s unyielding grip on the market, regardless of the potential harm.
While Ozempic-style drugs have shown effectiveness in weight loss and diabetes management, they also come with a long list of side effects, including hypoglycemia, breathing problems, facial swelling, and even cancer. The growing concern about their risks, combined with the outsized profits they generate, highlights the lack of effective oversight in the pharmaceutical industry and a broader health model that prioritizes curative treatments over preventative care.
